Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ARGENTA US HOLDINGS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to animal health
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FLOREO INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Source: Senate LDA
| ACCURAY INCORPORATED |
| 49 |
| 2015–2026 |
| ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 46 | 2018–2025 |
| FUJIREBIO DIAGNOSTICS, INC. | 43 | 2005–2018 |
| TERUMO BCT | 43 | 2013–2026 |
| U.S. RENAL CARE | 43 | 2016–2026 |
| SPARK THERAPEUTICS, INC. | 42 | 2015–2025 |
| TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) | 42 | 2017–2026 |
| VALEANT PHARMACEUTICALS INC | 42 | 2005–2015 |
| GLAUKOS CORPORATION (FKA AVEDRO, INC.) | 40 | 2015–2026 |
| ABBOTT | 39 | 2009–2017 |
| HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) | 37 | 2015–2023 |
| THE ALLERGY, ASTHMA & SINUS CENTER | 35 | 2018–2026 |
| ARDELYX INC | 34 | 2018–2026 |
| HARMONY BIOSCIENCES, LLC | 34 | 2019–2026 |
| BIOGEN INC. | 31 | 2019–2025 |
| BROOKDALE SENIOR LIVING INC. | 31 | 2019–2026 |
| CATALYST PHARMACEUTICALS | 30 | 2019–2026 |
| GILEAD SCIENCES, INC. | 30 | 2019–2026 |
| INSTITUTE FOR GENE THERAPIES | 30 | 2019–2026 |
| STERIS CORPORATION | 29 | 2020–2026 |
| Eagle Pharmaceuticals, Inc. | 28 | 2017–2024 |
| SUPERIOR AIR-GROUND AMBULANCE SERVICES | 26 | 2013–2019 |
| ACADIAN AMBULANCE | 25 | 2013–2019 |
| GENUS LIFESCIENCES | 25 | 2018–2026 |
| NEVRO CORPORATION | 25 | 2018–2025 |
| HOFFMAN LA-ROCHE | 24 | 2008–2012 |
| COVIDIEN | 23 | 2010–2015 |
| ENZYVANT THERAPEUTICS GMBH | 23 | 2018–2023 |
| ORGANON & CO. | 23 | 2021–2026 |
| STRATHSPEY CROWN | 23 | 2012–2017 |
| OTTOBOCK HEALTHCARE LP | 22 | 2016–2020 |
| ACELRX PHARMACEUTICALS, INC. | 21 | 2017–2022 |
| Exact Sciences Corporation | 21 | 2015–2020 |
| ACADIA HEALTHCARE, INC. | 20 | 2017–2021 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | 20 | 2017–2022 |
| SUPERNUS PHARMACEUTICALS, INC. | 20 | 2022–2026 |
| CARL ZEISS MEDITEC AG | 19 | 2016–2020 |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 19 | 2022–2026 |
| PHARMING HEALTHCARE, INC. | 19 | 2022–2026 |
| COLLEGIUM PHARMACEUTICAL | 17 | 2023–2026 |
| DELCATH SYSTEMS | 17 | 2010–2013 |
| MOMENTOUS | 17 | 2023–2026 |
| ACUFOCUS | 16 | 2012–2015 |
| ORTHOVITA INC | 16 | 2007–2010 |
| THE AMERICAN REGISTRY OF RADIOLOGIC TECHNOLOGISTS | 16 | 2019–2022 |
| VERTOS MEDICAL | 16 | 2010–2014 |
| FALCK USA, INC. | 15 | 2016–2019 |
| HEARTWARE, INC. | 15 | 2013–2016 |
| NYMOX PHARMACEUTICAL CORPORATION | 15 | 2019–2022 |
| REVANCE THERAPEUTICS INC. | 15 | 2021–2024 |
| WE WORK FOR HEALTH | 15 | 2023–2026 |
| CODAGENIX INC | 14 | 2019–2022 |
| ILLUMINA, INC. | 14 | 2023–2026 |
| JOHNSON & JOHNSON VISION | 14 | 2017–2020 |
| AMGEN, INC. | 13 | 2024–2026 |
| ANGIODYNAMICS INC | 13 | 2005–2009 |
| BIOTISSUE | 13 | 2024–2026 |
| NEUROTECH PHARMACEUTICALS | 13 | 2024–2026 |
| NOVOZYMES NORTH AMERICA, INC. | 13 | 2020–2023 |
| SPARC | 13 | 2024–2026 |
| BAYER (FORMERLY KNOWN AS CONCEPTUS) | 12 | 2011–2014 |
| BOSTON SCIENTIFIC CORP | 12 | 1999–2007 |
| CLAIM YOUR HEALTH DATA COALITION | 12 | 2016–2018 |
| GAMBRO BCT | 12 | 2001–2008 |
| NOVARTIS | 12 | 2004–2012 |
| scPharmaceuticals Inc. | 12 | 2023–2026 |
| AMYLIN | 11 | 2011–2012 |
| AVELLINO LABS USA | 11 | 2020–2022 |
| GENENTECH | 11 | 2012–2013 |
| HEALOGICS | 11 | 2016–2018 |
| SYNTHES | 11 | 2011–2013 |
| VAXART INC. | 11 | 2020–2022 |
| CV THERAPEUTICS | 10 | 2007–2009 |
| EMD SERONO, INC. | 10 | 2018–2019 |
| LIFEWARD (FORMERLY REWALK ROBOTICS, INC.) | 10 | 2022–2024 |
| MIMEDX GROUP, INC. | 10 | 2013–2015 |
| MOLECULAR INSIGHT PHARMACEUTICALS | 10 | 2005–2008 |
| SPECTRUM PHARMACEUTICALS, INC | 10 | 2016–2018 |
| TEK84 | 10 | 2022–2024 |
| CEPHALON, INC. | 9 | 2005–2008 |
| HEALGEN SCIENTIFIC | 9 | 2021–2022 |
| IOR PARTNERS | 9 | 2020–2023 |
| KENDAL NUTRICARE LTD | 9 | 2024–2026 |
| QUORUM HEALTH CORP. | 9 | 2020–2022 |
| SANTHERA PHARMACEUTICALS (USA), INC. | 9 | 2017–2018 |
| ADVANCED MEDICAL OPTICS | 8 | 2008–2009 |
| AURION BIOTECH | 8 | 2023–2025 |
| GAMBRO RENAL PRODUCTS | 8 | 2006–2008 |
| HARROW INC. | 8 | 2025–2026 |
| PHATHOM PHARMACEUTICALS | 8 | 2025–2026 |
| POLARITYTE, INC. | 8 | 2018–2020 |
| RECOR MEDICAL | 8 | 2025–2026 |
| SUMMIT BEHAVIORAL HEALTHCARE | 8 | 2025–2026 |
| ANTARES PHARMA | 7 | 2015–2016 |
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Early Detection of Vision Impairments for Children Act of 2025
Client: GLAUKOS CORPORATION (FKA AVEDRO, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
H.R. 2527, the Early Detection of Vision Impairments for Children Act
Early Detection of Vision Impairments for Children Act of 2025
Client: GLAUKOS CORPORATION (FKA AVEDRO, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
H.R. 2527, the Early Detection of Vision Impairments for Children Act
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
CBO Scoring Accountability Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Kidney Care Access Protection Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Kidney PATIENT Act of 2023
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Kidney PATIENT Act of 2023
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Cameron’s Law
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Cameron’s Law
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Cameron’s Law
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R. 2673, The American Innovation and R&D Competitiveness Act.
Cameron’s Law
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R. 2673, The American Innovation and R&D Competitiveness Act.
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652; FTC regulation of biopharma mergers and acquisitions
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
American Innovation and R&D Competitiveness Act of 2023
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R. 2673, The American Innovation and R&D Competitiveness Act.
ORPHAN Cures Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Issues related to treatment of autism spectrum disorder
Filing targets: Food & Drug Administration (FDA)
GOSSAMER BIO, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to FDA regulation of pharmaceuticals
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CARA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare reimbursement for medical devices
Issues related to Medicare reimbursement for medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARCUTIS BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FLEX VASCULAR via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues regarding coding and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HISTOSONICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare coverage of histotripsy procedures
Issues related to Medicare coverage of histotripsy procedures
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROVERUM MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare inpatient reimbursement for medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR AFFORDABLE PET CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANNKIND CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare/Medicaid reimbursement
Issues related to Diabetes care
Issues related to the Tricare Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAURDANT HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to health screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATARA BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to regulation of cell therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEMED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the No Surprises Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNOLIA MEDICAL TECHNOLOGIES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNUS MEDICAL, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medical Device Reimbursement
Issues related to Medical Device Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLOPLAST CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER INTRAOCULAR LENSES LIMITED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Reauthorization of the NO PAIN Act ; Medicare issues related to a non-opioid product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PAR HEALTH USA, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to pharmaceutical tariffs
Issues related to domestic pharmaceutical manufacturing; Issues related to supply chain resilience
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
INDIVIOR INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to substance use disorder
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUSPERA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENETIX BIOTHERAPEUTICS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to FDA regulation of rare disease therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OPUS GENETICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to FDA regulation of gene therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATEA PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to hepatitis C and prescription drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACME UNITED CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to trade
Issues related to medical products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AVALON HEALTHCARE SOLUTIONS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to diagnostic laboratory services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JCYTE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to cell therapy development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLERGY & ASTHMA ALLIANCE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to allergy & asthma reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOBIA MEDICAL, INC (FKA MICROTRANSPONDER) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAPRICOR via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to rare disease therapeutic development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ONE CALL, CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the Federal Employees Compensation Act (FECA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHATHOM PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to drug approval
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECOR MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to coverage of medical devices
Issues related to coverage of medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMMIT BEHAVIORAL HEALTHCARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to behavioral healthcare companies and substance use services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALEXION PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Medicare and Medicaid reimbursements for pharmaceuticals
Issues related to pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSMED, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare reimbursement of pharmaceutical products
General Issues of interest to pharmaceutical companies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARROW INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare rebates
Issues related to the regulation of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KENDAL NUTRICARE LTD via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to formula
Issues related to tariffs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BIOTISSUE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to tissue products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROTECH PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to approval of combination products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLUMINA, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
NIH Funding
Issues related to health care diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act of 2022; Issues relating to Medicare Part B and Medicare Part D drug pricing reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOMENTOUS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues Related to Defense and Human Performance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLLEGIUM PHARMACEUTICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMING HEALTHCARE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to FDA and rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUPERNUS PHARMACEUTICALS INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to the pharmaceutical industry
issues related to Medicare drug reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
General Issues of interest to pharmaceutical companies
Medicare reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STERIS CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
medical device manufacturing, servicing, and sterilization issues; FDA modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to regulation of prescription drugs and biologics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROOKDALE SENIOR LIVING INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to senior health care
issues related to senior housing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CATALYST PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
General FDA issues related to orphan drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the development and approval of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to medication affordability and access
Issues related to Medicare ESRD benefit and chronic kidney disease management
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSTITUTE FOR GENE THERAPIES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to the regulation of gene therapies; newborn screening; FDA appropriations
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENUS LIFESCIENCES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
health care coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. RENAL CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
ACCURAY INCORPORATED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to tariffs and trade
Issues related to Medicare payment for/access to radiation therapy services
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to diabetes and cardiovascular disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAUKOS CORPORATION (FKA AVEDRO, INC.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to medical device and drug coverage and reimbursement
H.R. 2527, the Early Detection of Vision Impairments for Children Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TERUMO BCT via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to supply chain constraints
Issues related to apheresis access and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SSI GROUP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to health IT and medical records
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIVANOVA USA INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
Issues related to epilepsy; issues related to telehealth
Medicare beneficiary access to procedures performed in ambulatory surgical centers; Medicare beneficiary access to treatments for depression and epilepsy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IBA PROTON THERAPY via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
issues related to coverage of proton therapy
issues related to coverage of proton therapy
FLOREO INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
issues related to treatment of autism spectrum disorder
ASTELLAS PHARMA US via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INNOVAGE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · 3T
issues related to the PACE program
issues relevant to the PACE program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HANSA BIOPHARMA AB via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to organ transplants; Medicare issues relevant to pharmaceutical companies
Issues related to organ transplants; Medicare issues relevant to pharmaceutical companies
ARTERA INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to cancer screening, diagnosis and digital pathology; Medicare reimbursement of laboratory developed tests and software as a medical device
Issues related to cancer screening, diagnosis and digital pathology; Medicare reimbursement of laboratory developed tests and software as a medical device
ARGENTA US HOLDINGS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to animal health
GOSSAMER BIO, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to FDA regulation of pharmaceuticals
CARA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to Medicare reimbursement for medical devices
Issues related to Medicare reimbursement for medical devices
CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RA
Medicare inpatient reimbursement for medial devices
SKY MARKETING CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · 3T
Issues related to hemp
Issues related to hemp
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURALINK CORP. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · 3T
Issues related to the development and commercialization of brain-computer interfaces
Issues related to coverage of medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARCUTIS BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to tariffs
HISTOSONICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to Medicare coverage of histotripsy procedures
Issues related to Medicare coverage of histotripsy procedures
FLEX VASCULAR via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
issues regarding coding and reimbursement
JCYTE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RA
Issues related to cell therapy development.
PROVERUM MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Issues related to medical devices
CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · third_quarter · RR
Medicare inpatient reimbursement for medical devices
COALITION FOR AFFORDABLE PET CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Educate policymakers about the veterinary medicine landscape
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEURALINK CORP. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to the development and commercialization of brain-computer interfaces
Issues related to coverage of medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MANNKIND CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to the Tricare Program
Issues related to Medicare/Medicaid reimbursement
Issues related to Diabetes care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GAURDANT HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to health screening
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ATARA BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to regulation of cell therapies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEMED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to the No Surprises Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNOLIA MEDICAL TECHNOLOGIES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAGNUS MEDICAL, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to Medical Device Reimbursement
Issues related to Medical Device Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLOPLAST CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RAYNER INTRAOCULAR LENSES LIMITED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to Reauthorization of the NO PAIN Act ; Medicare issues related to a non-opioid product
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Matters affecting Medicare/Medicaid Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SKY MARKETING CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to hemp
Issues related to hemp
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PAR HEALTH USA, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to pharmaceutical tariffs
Issues related to domestic pharmaceutical manufacturing; Issues related to supply chain resilience
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIVIOR INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2026 · second_quarter · Q2
Issues related to substance use disorder
Filing targets: HOUSE OF REPRESENTATIVES, SENATE